Skip to content

Danish Biotech Takes a Leap in New York City

4.27.2016  17:21
The Trade Council North America introduced key Danish players in biotech to the US market at the #DKBioNYC16 conference

biotech conf1

The Trade Council North America held the inaugural Danish Biotech Conference #DKBioNYC16 April 12-13, introducing key players in Danish biotech to the US market.

The Danish Biotech Conference in New York brought together companies such as Zealand, Symphogen and Galecto Biotech and covered all aspects of market entry.

Panels and presentations were held on:
•The US IPO process - with NASDAQ
•Pricing and reimbursement
•Navigating the FDA-system

Throughout the program, the Danish companies were matched with leading investors in the US industry in 1-1 meetings. The conference concept was launched by The Trade Council in New York City to address the top concerns and needs of Danish biotechs trying to work in some form or another in the US.

“What really made the difference is that we got feedback from CEOs, CFOS, and Chairmen of our Danish biotechs who could be ‘cornerstone’ companies to a trip like this, as well as from American investors. All in all we got advice and feedback from six Danes, and five Americans, and that is what made this such an outstanding success,” said Megan Dow, Ph.D., Senior Life Science Advisor in the New York Office speaking about her advisory board for the conference.
“By listening to what would set a program apart from the others available in the industry, we created a great product that was tailormade for our clients.”

Matching partners for the future
In addition to the conference’s panel sessions and 1x1 meetings, the Danish biotechs were given the opportunity to network with investors at a reception hosted by the Ambassador, Consul General of Denmark in New York, and have the unique opportunity of ringing the opening bell at NASDAQ.

The participants heard from the top life science funds in the industry, including Aisling Capital, Venrock, and Omega Funds, and 40 one-on-one meetings were held with funds like Orbimed, Baker Brothers, Federated Investments, and many more. The conference also addressed top concerns for Danish biotechs, such as pricing and reimbursement strategies in the US, the FDA, the IPO process, and how to work with Pharma, in a setting where companies were able to ask questions specific and relevant to them.

“The level of exclusive access, and the intimate networking is what we were told set this apart from the beginning. Being able to go to NASDAQ was certainly a significant bonus to all participants too!” said Megan Dow.

The NASDAQ ceremony was part of NASDAQ’s sponsorship. Other sponsors included large international players incl. Citibank, BDO, MCGuireWoods, and Trout Group. Novo A/S and Lundbeckfonden A/S also supported the conference.

“I hope that this can serve as a model for how we can build collaborations with local market players for our other industry and missions as well. The sponsors were asking to get involved and have already asked about being involved next time,” said Megan Dow, noting that the key attraction for sponsors was the unfettered access to potential new clients in Denmark.

Company and press contact:
Megan Dow, Senior Advisor for Life Sciences, Trade Council North America
megdow@um.dk / +1 212 705 4915